tiprankstipranks
Advertisement
Advertisement

MIST Stock Latest News

Milestone Pharmaceuticals enrolls first patient in ReVeRA-301 pivotal trial
The FlyMilestone Pharmaceuticals enrolls first patient in ReVeRA-301 pivotal trial
2d ago
MIST
Cantor starts Milestone Pharmaceuticals at Overweight, sees 200% upside
PremiumThe Fly
Cantor starts Milestone Pharmaceuticals at Overweight, sees 200% upside
3d ago
MIST
Milestone Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Milestone Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
3d ago
MIST
Milestone Pharmaceuticals reports Q2 EPS (21c), consensus (19c)
PremiumThe Fly
Milestone Pharmaceuticals reports Q2 EPS (21c), consensus (19c)
6d ago
MIST
Analyst Ritu Baral Initiates Buy on Cardamyst, Citing Strong Early Launch Metrics, Improving Reimbursement Outlook, and Solid Cash Runway
PremiumRatings
Analyst Ritu Baral Initiates Buy on Cardamyst, Citing Strong Early Launch Metrics, Improving Reimbursement Outlook, and Solid Cash Runway
10d ago
MIST
Milestone Pharmaceuticals’ Earnings Call Flags Risk and Momentum
PremiumCompany AnnouncementsMilestone Pharmaceuticals’ Earnings Call Flags Risk and Momentum
11d ago
MIST
Milestone Pharmaceuticals: Strong CARDAMYST Launch Metrics and Expanded Coverage Support Unchanged $8 Price Target and Buy Rating
Premium
Ratings
Milestone Pharmaceuticals: Strong CARDAMYST Launch Metrics and Expanded Coverage Support Unchanged $8 Price Target and Buy Rating
11d ago
MIST
Milestone Pharmaceuticals (MIST) Q2 Earnings Cheat Sheet
Premium
Pre-Earnings
Milestone Pharmaceuticals (MIST) Q2 Earnings Cheat Sheet
13d ago
MIST
Milestone Pharmaceuticals Shareholders Approve Governance and Compensation Measures
PremiumCompany Announcements
Milestone Pharmaceuticals Shareholders Approve Governance and Compensation Measures
2M ago
8K
MIST
Milestone Pharmaceuticals’ Earnings Call Signals Early Momentum
PremiumCompany Announcements
Milestone Pharmaceuticals’ Earnings Call Signals Early Momentum
3M ago
MIST
Milestone Pharmaceuticals’ Earnings Call Highlights Early Launch Momentum
PremiumCompany Announcements
Milestone Pharmaceuticals’ Earnings Call Highlights Early Launch Momentum
3M ago
MIST
Milestone Pharmaceuticals files $300M mixed securities shelf
PremiumThe Fly
Milestone Pharmaceuticals files $300M mixed securities shelf
3M ago
MIST
Buy Rating Reiterated on Milestone as Cardamyst Traction Grows and AFib Program Advances; $8 Price Target Unchanged
PremiumRatingsBuy Rating Reiterated on Milestone as Cardamyst Traction Grows and AFib Program Advances; $8 Price Target Unchanged
3M ago
MIST
Analyst Reiterates Buy on MIST, Maintains $8 Price Target on Strong CARDAMYST Launch and Expanded AFib Opportunity
Premium
Ratings
Analyst Reiterates Buy on MIST, Maintains $8 Price Target on Strong CARDAMYST Launch and Expanded AFib Opportunity
3M ago
MIST
Milestone Pharmaceuticals reports Q1 EPS (20c), consensus 19c
Premium
The Fly
Milestone Pharmaceuticals reports Q1 EPS (20c), consensus 19c
3M ago
MIST
Milestone Pharmaceuticals (MIST) Q1 Earnings Cheat Sheet
PremiumPre-Earnings
Milestone Pharmaceuticals (MIST) Q1 Earnings Cheat Sheet
3M ago
MIST
Milestone Pharmaceuticals provides details on RESET-PSVT trial
PremiumThe Fly
Milestone Pharmaceuticals provides details on RESET-PSVT trial
5M ago
MIST
Milestone Pharmaceuticals initiated with a Strong Buy at Raymond James
PremiumThe Fly
Milestone Pharmaceuticals initiated with a Strong Buy at Raymond James
5M ago
MIST
Milestone Pharmaceuticals initiated with a Strong Buy at Raymond James
PremiumThe Fly
Milestone Pharmaceuticals initiated with a Strong Buy at Raymond James
5M ago
MIST
Milestone Pharmaceuticals announces availability of Cardamyst on Express Scripts
PremiumThe FlyMilestone Pharmaceuticals announces availability of Cardamyst on Express Scripts
5M ago
MIST
Regulatory Disruptions Pose Material Operational Risks for Milestone Pharmaceuticals
Premium
Company Announcements
Regulatory Disruptions Pose Material Operational Risks for Milestone Pharmaceuticals
5M ago
MIST
Milestone: Early CARDAMYST Launch Progress and Solid Cash Position Underscore Buy Rating and $8 Target
Premium
Ratings
Milestone: Early CARDAMYST Launch Progress and Solid Cash Position Underscore Buy Rating and $8 Target
5M ago
MIST

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >